InnoCan Pharma Corporation reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was USD 2.56 million compared to USD 0.196 million a year ago. Net loss was USD 3.76 million compared to USD 10.05 million a year ago.

Basic loss per share from continuing operations was USD 0.016 compared to USD 0.05 a year ago.